You searched for "CET"

1694 results found

The final step

Not long after securing my fellowship in London I was successful at interview for a consultant post at Singleton Hospital, Swansea. The interview took place before I had actually started in London and besides the basic things that are asked...

Ozurdex in epiretinal membrane surgery

This was a prospective multicentre pilot study, looking at the effect of Ozurdex on visual acuity (VA) and central retinal thickness (CRT) in patients undergoing surgery for epiretinal membrane (ERM). Twelve eyes of 12 patients were included in the study....

Lucentis for pseudophakic CMO

Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...

Making a life-changing difference in Bangladesh

It has always been a desire of mine to volunteer in a ‘vision aid’ type project abroad, but due to various factors I had not been able to fulfil this desire until very recently. A gentleman called Mizanur Rahman (founder...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection

This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...

Corneal thickness in patients with diabetic peripheral neuropathy

This cross-sectional study assessed corneal thickness in association with diabetic peripheral neuropathy (DPN) severity. The study also tried to identify the layer of the cornea most affected by DPN status. Performed at the University of Michigan the study included three...

Comparison of changes in ECD and CCT between CPS and FLACS

This is an intraindividual randomised clinical trial of 134 eyes from 67 patients, one eye was treated with femtosecond laser-assisted cataract surgery (FLACS) (including pretreatment of main incision, side port, capsulotomy and lens fragmentation) and the fellow eye received conventional...

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...

RaScaL Study

The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...